A5003929069- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
- Cervical Cancer and HPV Research
- Intraperitoneal and Appendiceal Malignancies
- Endometriosis Research and Treatment
- PARP inhibition in cancer therapy
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Palliative Care and End-of-Life Issues
- Renal cell carcinoma treatment
- Reproductive System and Pregnancy
- Colorectal and Anal Carcinomas
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer survivorship and care
- Reproductive Biology and Fertility
- Gynecological conditions and treatments
- Estrogen and related hormone effects
- Economic and Financial Impacts of Cancer
- DNA Repair Mechanisms
University of Pennsylvania Health System
2016-2025
University of Pennsylvania
2015-2025
Gynecologic Oncology Group
2009-2025
Penn Center for AIDS Research
2021-2024
Abramson Cancer Center
2024
Cancer Institute (WIA)
2023-2024
Cleveland Clinic
2023-2024
University Hospitals Seidman Cancer Center
2023-2024
City Of Hope National Medical Center
2023
California University of Pennsylvania
2023
The development of noninvasive methods to detect and monitor tumors continues be a major challenge in oncology. We used digital polymerase chain reaction-based technologies evaluate the ability circulating tumor DNA (ctDNA) 640 patients with various cancer types. found that ctDNA was detectable >75% advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, head neck cancers, but less than 50% primary brain, renal, prostate, or thyroid cancers. In...
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly uterine cancer carcinoma corpus) is most common malignancy female genital tract in United States. It estimated that 65,950 new cases will have occurred 2022, with 12,550 deaths resulting from disease. Endometrial includes pure endometrioid and carcinomas high-risk histology (including serous carcinoma, clear cell carcinosarcoma [also malignant mixed Müllerian tumor], undifferentiated/dedifferentiated...
Mutant DNA from ovarian and endometrial tumors can be detected in Pap smear specimens through massively parallel sequencing.
The NCCN Guidelines for Cervical Cancer provide recommendations diagnostic workup, staging, and treatment of patients with the disease. These Insights focus on recent updates to guidelines, including changes first- second-line systemic therapy recurrent or metastatic disease, emerging evidence a new histopathologic classification system HPV-related endocervical adenocarcinoma.
The NCCN Guidelines for Uterine Neoplasms provide recommendations diagnostic workup, clinical staging, and treatment options patients with endometrial cancer or uterine sarcoma. These Insights focus on the recent addition of molecular profiling information to aid in accurate diagnosis, classification, sarcomas.
The NCCN Guidelines for Cervical Cancer provide recommendations all aspects of management cervical cancer, including the diagnostic workup, staging, pathology, and treatment. guidelines also include details on histopathologic classification cancer regarding features, molecular profiles, clinical outcomes. treatment landscape advanced is evolving constantly. These Insights a summary recent updates systemic therapy recurrent or metastatic disease.
Vulvar cancer is annually diagnosed in an estimated 6,470 individuals and the vast majority are histologically squamous cell carcinomas. accounts for 5% to 8% of gynecologic malignancies. Known risk factors vulvar include increasing age, infection with human papillomavirus, cigarette smoking, inflammatory conditions affecting vulva, immunodeficiency. Most neoplasias at early stages. Rarer histologies exist melanoma, extramammary Paget’s disease, Bartholin gland adenocarcinoma, verrucous...
These NCCN Clinical Practice Guidelines in Oncology for Cervical Cancer focus on early-stage disease, because it occurs more frequently the United States. After careful clinical evaluation and staging, primary treatment of cervical cancer is either surgery or radiotherapy. guidelines include fertility-sparing non-fertility-sparing those with which disease confined to uterus. A new algorithm was added select patients stage IA IB1 disease..
ObjectivePlatinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited treatment options. Preclinical data suggest that poly(ADP-ribose) polymerase inhibitors (PARPi) and ataxia telangiectasia Rad3-related kinase (ATRi) are synergistic. CAPRI (NCT03462342) is an investigator-initiated study of olaparib plus ceralasertib in recurrent HGSOC. Herein, we present results from the platinum-resistant cohort.MethodsA Simon 2-stage design was utilized. Platinum-resistant HGSOC patients...
Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to PARP (PARPi) overcomes PARPi resistance in high-grade serous ovarian cancer (HGSOC) cell mouse models. We present the results an investigator-initiated study combination (olaparib) ATRi (ceralasertib) patients with acquired PARPi-resistant HGSOC.Eligible had recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR)-deficient (HRD) HGSOC clinically benefited from (response by imaging/CA-125...
To evaluate the risk of epithelial ovarian cancer (EOC) recurrence in patients with rising serum antigen 125 (CA-125) levels that remain below upper limit normal (< 35 U/mL).All treated for EOC between September 1997 and March 2003 were identified screened retrospectively following: (1) elevated CA-125 at time diagnosis, (2) complete clinical radiographic response (CR) to initial treatment normalization CA-125, (3) least three serial determinations remained within range, (4) and/or...
Abstract BACKGROUND. The objective of this study was to evaluate the role secondary cytoreductive surgery in outcome patients who had recurrent epithelial ovarian carcinoma that limited ≤5 recurrence sites within abdomen or pelvis on preoperative imaging studies and attempt define selection criteria associated with improved survival, specific attention number lesions suspicious for disease. METHODS. Patients underwent surgical cytoreduction cancer between September 1997 March 2005 were...
The TP53 mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%, but a stringent analysis of using purified epithelial samples not yet performed accurately assess the correlate it with histologic grade. purpose this study was mutational profile relatively large series high-grade (53 primary 18 recurrent) 13 low-grade tumors DNA isolated from affinity-purified tumor cells vitro drug resistance. All were affinity purified, analyzed for mutations exons...
Abstract Tumors often display mechanisms to avoid or suppress immune recognition. One such mechanism is the shedding of gangliosides into local tumor microenvironment, and a high concentration circulating associated with poor prognosis. In this study, we identify ganglioside GD3, which was isolated from polar lipid fraction ovarian cancer–associated ascites, as an inhibitory factor that prevents innate activation natural killer T (NKT) cells. Purified GD3 displayed affinity for both human...
The prognostic significance of isolated tumor cells (≤0.2 mm) in sentinel lymph nodes (SLNs) endometrial cancer patients is still unclear. Our aim was to assess the value with low risk who underwent SLN biopsy and did not receive adjuvant therapy. Outcomes were compared node negative patients. Patients SLNs-isolated between 2013 2019 identified from 15 centers worldwide, while Mayo Clinic, Rochester, 2018. Only (stage IA, endometrioid histology, grade 1 or 2) any therapy included. Primary...